Investors will be watching China's third quarter GDP for clues on its economic recovery, along with retail sales and urban unemployment data.
GP1-1 drugs, originally developed as a treatment for diabetes, are shaking up some sectors — from owners of dialysis centers to bariatric surgery providers and the food industry. But one investment advisor, Brian Krawez, president of Scharf Investments, says there are opportunities for two stocks. 'We think the selloff has been unwarranted and creates a buying opportunity,' Brian Krawez, president of Scharf Investments, says of one of the stocks.
Pro subscribers can read more here. — Weizhen Tan
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Asia markets open weaker as investors look ahead to China GDP, Japan inflation dataChina will release its third-quarter gross domestic product, while Japan’s inflation data and South Korea’s rate decision are also expected this…
Weiterlesen »
Asia markets dip as investors look ahead to China GDP, Japan inflation dataChina will release its third-quarter gross domestic product, while Japan’s inflation data and South Korea’s rate decision are also expected this…
Weiterlesen »
China'a Q3 GDP growth seen slowing to 4.4% as headwinds persist: Reuters pollChina'a Q3 GDP growth seen slowing to 4.4% as headwinds persist: Reuters poll
Weiterlesen »
Asian stocks recover some losses; China GDP, M.East tensions in focusAsian stocks recover some losses; China GDP, M.East tensions in focus
Weiterlesen »
Marketmind: China GDP eyed as global cross currents swirlMarketmind: China GDP eyed as global cross currents swirl
Weiterlesen »
China Gross Domestic Product (GDP) QoQGet the GDP (QoQ) results in real time as they're announced and see the immediate global market impact.
Weiterlesen »